

Cipla brings revolutionary diabetes management solution to India

11 December 2024 | News

Afrezza is the first and only rapid-acting insulin that can be inhaled



Mumbai-based pharma firm Cipla has announced regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) for the exclusive distribution and marketing of Afrezza (insulin human) Inhalation Powder in India.

Developed and manufactured by MannKind Corporation (USA), Afrezza offers a groundbreaking treatment designed to improve glycemic control in adults with diabetes mellitus. This partnership is set to transform diabetes care in India by introducing a patient-centric solution that is both innovative and convenient, empowering millions to manage their health with greater ease.

Afrezza is the first and only rapid-acting insulin that can be inhaled, providing a non-injectable alternative for individuals with both type 1 and type 2 diabetes. Administered through an inhaler at the beginning of a meal, it quickly dissolves upon inhalation into the lungs, delivering insulin to the bloodstream.

This process enables it to start working in as little as 12 minutes, closely mimicking the body's natural insulin response. Its effects last for 2-3 hours, making it particularly effective in reducing the rapid blood sugar spikes associated with meals while eliminating the need for multiple daily insulin injections.

Afrezza has been extensively evaluated in over 70 clinical studies involving more than 3,000 patients globally. With over a decade of approval in the United States, it has been prescribed to tens of thousands of patients. Under the partnership agreement, MannKind will supply Afrezza to Cipla, which will handle the drug's sales and marketing activities in India.